Nukleäre Hormonrezeptoren: Perspektiven der Dermatotherapie^[*]

Zusammenfassung

Nukleäre Hormonrezeptoren sind Transkriptionsfaktoren, deren Aktivität von Liganden reguliert wird, die sowohl endogener als auch exogen-pharmakologischer Natur sein können. Zu den Pharmaka, die durch Bindung an nukleäre Hormonrezeptoren wirken, gehören die in der Dermatotherapie außerordentlich erfolgreichen Glukokortikosteroide, die Retinoide und die Vitamin-D-Analoga. Neue Perspektiven eröffnen die Peroxisome-Proliferator-Activated-Rezeptoren (PPAR), die Liver-X-Rezeptoren (LXR) und der Pregnane-X-Rezeptor (PXR). Diese besitzen anti-inflammatorische Eigenschaften und beeinflussen weitere Aspekte der Hautphysiologie wie Zelldifferenzierung, Energie-, Lipid- sowie Zytochrom-Stoffwechsel. PPAR-, LXR- und PXR-Liganden üben auf diese Weise positive Wirkungen auf die kutane Homöostase aus und sind Kandidaten für zukünftige Entwicklungen in der Dermatotherapie.

Abstract

Nuclear hormone receptors act as transcription factors that can be activated by ligands of either endogenous or exogenous origin. Pharmacological ligands acting via nuclear hormone receptors have been exceptionally succesful in the treatment of skin disease, among them glucocorticoids, retinoids and vitamin D analoga. New opportunities arise from targeting Perioxisome Proliferator-Activated Receptors (PPAR), Liver X Receptors (LXR) and the Pregnane X Receptor (PXR). These receptors exhibit anti-inflammatory activities and modulate additional aspects of cutaneous physiology including differentiation, energy-, lipid-, and cytochrome metabolism. Ligands of PPAR, LXR and PXR have beneficial effects on skin homeostasis and may represent promising targets for future therapeutic approaches in dermatology.

^* Vorgetragen beim 11. Jahressymposion der Berliner Stiftung für Dermatologie. Wissenschaftliche Sitzung anlässlich des 75. Geburtstags von Herrn Prof. Dr. Dr. h. c. mult. C. E. Orfanos am 1. – 2. Juli 2011 in Berlin.

• Literatur

• 1 Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952; 19: 101-102
• 2 Hunter R, Pinkus H. The effect of oral vitamin A on the number of keratin cells of human epidermis. J Invest Dermatol 1961; 37: 459-460
• 3 Kligman AM, Fulton Jr JE, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969; 99: 469-476
• 4 Frost P, Weinstein GD. Topical administration of Vitamin A acid for ichthyosiform dermatoses and psoriasis. JAMA 1969; 207: 1863-1868
• 5 Orfanos CE, Schmidt HW, Mahrle G et al. Effect of vitamin A acid (VAA) on psoriasis. Topical combined therapy using corticoids. Two new VAA preparations for oral administration. Arch Dermatol Forsch 1972; 244: 424-426
• 6 Apisarnthanarax N, Duvic M. Cutaneous T-cell lymphoma. New immunomodulators. Dermatol Clin 2001; 19: 737-748
• 7 Kragballe K, Beck HI, Sogaard H. Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study. Br J Dermatol 1988; 119: 223-230
• 8 van de Kerkhof PC, van Bokhoven M, Zultak M et al. A double-blind study of topical 1 alpha,25-dihydroxyvitamin D3 in psoriasis. Br J Dermatol 1989; 120: 661-664
• 9 Henderson CA, Papworth-Smith J, Cunliffe WJ et al. A double-blind, placebo-controlled trial of topical I,25-dihydroxycholecalciferol in psoriasis. Br J Dermatol 1989; 121: 493-496
• 10 Orfanos CE, Runne U. Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis. Br J Dermatol 1976; 95: 101-103
• 11 Orfanos CE, Runne U. Tissue changes in psoriatic plaques after oral administration of retinoid. Dermatologica 1978; 157 (Suppl 1): 19-25
• 12 Goerz G, Orfanos CE. Systemic treatment of psoriasis with a new aromatic retinoid. Preliminary evaluation of a multicenter controlled study in the Federal Republic of Germany. Dermatologica 1978; 157 (Suppl 1): 38-44
• 13 Orfanos CE, Goerz G. Oral psoriasis treatment with a new aromatic retinoid (Ro 10-9359): a multi-centre controlled study of 291 patients (preliminary results). Dtsch Med Wochenschr 1978; 103: 195-199
• 14 Orfanos CE, Pullmann H, Sterry W et al. Retinoid PUVA (RePUVA): systemic combination therapy in psoriasis. Z Hautkr 1978; 53: 494-504
• 15 Orfanos CE, Kurka M, Strunk V. Oral treatment of keratosis follicularis with a new aromatic retinoid. Arch Dermatol 1978; 114: 1211-1214
• 16 Orfanos CE, Landes E, Bloch PH. Treatment of pustular psoriasis with a new aromatic retinoid (RO 10-9359). Report on 9 generalized and 8 localized cases. Ann Dermatol Venereol 1978; 105: 807-811
• 17 Orfanos CE, Steigleder GK, Pullmann H et al. Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis. Acta Derm Venereol 1979; 59: 241-244
• 18 Orfanos CE, Mahrle G, Goerz G et al. Laboratory investigations in patients with generalized psoriasis under oral retinoid treatment. A multicenter study of computerized data. Dermatologica 1979; 159: 62-70
• 19 Orfanos CE, Pullmann H, Runne U et al. Treatment of psoriasis using vitamin A, vitamin A acid and oral retinoids. Hautarzt 1979; 30: 124-133
• 20 Gillenberg A, Immel C, Orfanos CE. Influence of oral retinoid on the cell kinetic of normal human epidermis. Arch Dermatol Res 1980; 269: 331-335
• 21 Tsambaos D, Mahrle G, Orfanos CE. Epidermal changes induced by oral excess of aromatic retinoid in guinea pigs. Arch Dermatol Res 1980; 267: 141-152
• 22 Tsambaos D, Orfanos CE. Ultrastructural evidence suggesting an immunomodulatory activity of oral retinoid. Its effect on dermal components in psoriasis. Br J Dermatol 1981; 104: 37-45
• 23 Bauer R, Orfanos CE. Trimethylmethoxyphenyl-retinoic acid (Ro 10-1670) inhibits mitogen-induced DNA-synthesis in peripheral blood lymphocytes in vitro. Br J Dermatol 1981; 105: 19-24
• 24 Gollnick H, Luley C, Schwartzkopff W et al. Changes in serum lipid fractions as a side effect of oral retinoids. Z Hautkr 1982; 57: 1255-1267
• 25 Orfanos CE, Bauer R. Evidence for anti-inflammatory activities of oral synthetic retinoids: experimental findings and clinical experience. Br J Dermatol 1983; 109 (Suppl 25): 55-60
• 26 Stadler R, Marcelo CL, Voorhees JJ et al. Effect of a new retinoid, arotinoid (Ro 13-6298), on in vitro keratinocyte proliferation and differentiation. Acta Derm Venereol 1984; 64: 405-411
• 27 Stadler R, Muller R, Detmar M et al. Retinoids and keratinocyte differentiation in vitro. Dermatologica 1987; 175 (Suppl 1): 45-55
• 28 Rinck G, Gollnick H, Orfanos CE. Duration of contraception after etretinate. Lancet 1989; 1: 845-846
• 29 Imcke E, Ruszczak Z, Mayer-da Silva A et al. Cultivation of human dermal microvascular endothelial cells in vitro: immunocytochemical and ultrastructural characterization and effect of treatment with three synthetic retinoids. Arch Dermatol Res 1991; 283: 149-157
• 30 Zouboulis CC, Korge B, Akamatsu H et al. Effects of 13-cis-retinoic acid, all-trans-retinoic acid, and acitretin on the proliferation, lipid synthesis and keratin expression of cultured human sebocytes in vitro. J Invest Dermatol 1991; 96: 792-797
• 31 Chawla A, Repa JJ, Evans RM et al. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-1870
• 32 Shulman AI, Mangelsdorf DJ. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 2005; 353: 604-615
• 33 Schmuth M, Jiang YJ, Dubrac S et al. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008; 49: 499-509
• 34 Hummasti S, Hong C, Bensinger SJ et al. HRASLS3 is a PPARgamma-selective target gene that promotes adipocyte differentiation. J Lipid Res 2008; 49: 2535-2544
• 35 Chandra V, Huang P, Hamuro Y et al. Structure of the intact PPAR-gamma-RXR-nuclear receptor complex on DNA. Nature 2008; 456: 350-356
• 36 Schmuth M, Elias PM, Feingold KR. Beyond glucocorticoids, retinoids and vitamin D--the evolution of nuclear hormone type transcription factor targeting in the skin. J Dtsch Dermatol Ges 2003; 1: 352-362
• 37 Schmuth M, Watson RE, Deplewski D et al. Nuclear hormone receptors in human skin. Horm Metab Res 2007; 39: 96-105
• 38 Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 1998; 139: 2748-2754
• 39 Rivier M, Safonova I, Lebrun P et al. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol 1998; 111: 1116-1121
• 40 Michalik L, Desvergne B, Tan NS et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 2001; 154: 799-814
• 41 Schmuth M, Schoonjans K, Yu QC et al. Role of peroxisome proliferator-activated receptor alpha in epidermal development in utero. J Invest Dermatol 2002; 119: 1298-1303
• 42 Komuves LG, Hanley K, Lefebvre AM et al. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 2000; 115: 353-360
• 43 Yang Q, Yamada A, Kimura S et al. Alterations in skin and stratified epithelia by constitutively activated PPARalpha. J Invest Dermatol 2006; 126: 374-385
• 44 Dubrac S, Schmuth M. (P)PARsing epidermal development. J Invest Dermatol 2006; 126: 241-242
• 45 Hanley K, Komuves LG, Ng DC et al. Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem 2000; 275: 11484-11491
• 46 Thuillier P, Brash AR, Kehrer JP et al. Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. Biochem J 2002; 366: 901-910
• 47 Hanley K, Jiang Y, Crumrine D et al. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J Clin Invest 1997; 100: 705-712
• 48 Rosenfield RL, Deplewski D, Greene ME. Peroxisome proliferator-activated receptors and skin development. Horm Res 2000; 54: 269-274
• 49 Rosenfield RL, Kentsis A, Deplewski D et al. Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors. J Invest Dermatol 1999; 112: 226-232
• 50 Chen W, Yang CC, Sheu HM et al. Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J Invest Dermatol 2003; 121: 441-447
• 51 Dubrac S, Schmuth M. PPAR-alpha in cutaneous inflammation. Dermatoendocrinol 2011; 3: 23-26
• 52 Dubrac S, Stoitzner P, Pirkebner D et al. Peroxisome proliferator-activated receptor-alpha activation inhibits Langerhans cell function. J Immunol 2007; 178: 4362-4372
• 53 Hatano Y, Man MQ, Uchida Y et al. Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. J Allergy Clin Immunol 2010; 125: 160-169 e1 – 5
• 54 Staumont-Salle D, Abboud G, Brenuchon C et al. Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 2008; 121: 962-968 e6
• 55 Sheu MY, Fowler AJ, Kao J et al. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 2002; 118: 94-101
• 56 Dubrac S, Elentner A, Schoonjans K et al. Lack of IL-2 in PPAR-alpha-deficient mice triggers allergic contact dermatitis by affecting regulatory T cells. Eur J Immunol 2011; 41: 1980-1991
• 57 Hatano Y, Elias PM, Crumrine D et al. Efficacy of combined peroxisome proliferator-activated receptor-alpha ligand and glucocorticoid therapy in a murine model of atopic dermatitis. J Invest Dermatol 2011; 131: 1845-1852
• 58 Demerjian M, Choi EH, Man MQ et al. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp Dermatol 2009; 18: 643-649
• 59 Eichenfield LF, McCollum A, Msika P. The benefits of sunflower oleodistillate (SOD) in pediatric dermatology. Pediatr Dermatol 2009; 26: 669-675
• 60 De Belilovsky C, Roo-Rodriguez E, Baudouin C et al. Natural peroxisome proliferator-activated receptor-alpha agonist cream demonstrates similar therapeutic response to topical steroids in atopic dermatitis. J Dermatolog Treat 2010; 22: 359-365
• 61 Kippenberger S, Loitsch SM, Grundmann-Kollmann M et al. Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. J Invest Dermatol 2001; 117: 1430-1436
• 62 Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006; 116: 590-597
• 63 Westergaard M, Henningsen J, Svendsen ML et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol 2001; 116: 702-712
• 64 Matsuura H, Adachi H, Smart RC et al. Correlation between expression of peroxisome proliferator-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol Cell Endocrinol 1999; 147: 85-92
• 65 Tan NS, Michalik L, Noy N et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 2001; 15: 3263-3277
• 66 Man MQ, Choi EH, Schmuth M et al. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol 2006; 126: 386-392
• 67 Schmuth M, Haqq CM, Cairns WJ et al. Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 2004; 122: 971-983
• 68 Romanowska M, al Yacoub N, Seidel H et al. PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 2008; 128: 110-124
• 69 al Yacoub N, Romanowska M, Krauss S et al. PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 2008; 128: 1940-1949
• 70 Bility MT, Devlin-Durante MK, Blazanin N et al. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis. Carcinogenesis 2008; 29: 2406-2414
• 71 Zhu B, Bai R, Kennett MJ et al. Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase 2. Mol Cancer Ther 2010; 9: 3267-3277
• 72 Bility MT, Zhu B, Kang BH et al. Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol Sci 2010; 113: 27-36
• 73 Kim DJ, Bility MT, Billin AN et al. PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 2006; 13: 53-60
• 74 Peters JM, Lee SS, Li W et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000; 20: 5119-5128
• 75 Man MQ, Barish GD, Schmuth M et al. Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol 2008; 128: 370-377
• 76 Choi JH, Banks AS, Estall JL et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010; 466: 451-456
• 77 Mao-Qiang M, Fowler AJ, Schmuth M et al. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol 2004; 123: 305-312
• 78 Demerjian M, Man MQ, Choi EH et al. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 2006; 15: 154-160
• 79 Ellis CN, Varani J, Fisher GJ et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000; 136: 609-616
• 80 Zhang Q, Southall MD, Mezsick SM et al. Epidermal peroxisome proliferator-activated receptor gamma as a target for ultraviolet B radiation. J Biol Chem 2005; 280: 73-79
• 81 Ochiai M, Niki T, Ashida M. Immunocytochemical localization of beta-1,3-glucan recognition protein in the silkworm, Bombyx mori. Cell Tissue Res 1992; 268: 431-437
• 82 Russell LE, Harrison WJ, Bahta AW et al. Characterization of liver X receptor expression and function in human skin and the pilosebaceous unit. Exp Dermatol 2007; 16: 844-852
• 83 Komuves LG, Schmuth M, Fowler AJ et al. Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis. J Invest Dermatol 2002; 118: 25-34
• 84 Schmuth M, Elias PM, Hanley K et al. The effect of LXR activators on AP-1 proteins in keratinocytes. J Invest Dermatol 2004; 123: 41-48
• 85 Shen Q, Bai Y, Chang KC et al. Liver X receptor-retinoid X receptor (LXR-RXR) heterodimer cistrome reveals coordination of LXR and AP1 signaling in keratinocytes. J Biol Chem 2011; 286: 14554-14563
• 86 Fowler AJ, Sheu MY, Schmuth M et al. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 2003; 120: 246-255
• 87 Geyeregger R, Zeyda M, Bauer W et al. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin. Blood 2007; 109: 4288-4295
• 88 Chang KC, Shen Q, Oh IG et al. Liver X receptor is a therapeutic target for photoaging and chronological skin aging. Mol Endocrinol 2008; 22: 2407-2419
• 89 Ihunnah CA, Jiang M, Xie W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta 2011; 1812: 956-963
• 90 Dubrac S, Elentner A, Ebner S et al. Modulation of T lymphocyte function by the pregnane X receptor. J Immunol 2010; 184: 2949-2957
• 91 Tsankov N, Grozdev I. Rifampicin in the treatment of psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 93-95